Stem cell biotech company Bioheart ($BHRT) has had a rough 2015 so far. Could this year be a decisive, negative tipping point for the company? It has a number of clinical trials going, but from my view things seem increasingly uncertain. An oddity amongst stem cell biotechs, Bioheart and its leadership have at times seemed to toy […]
Bioheart on the edge in 2015? Read More »
The paper that came out Wednesday from a research group in China reporting the first genetic modification of human embryos has sparked a lot of discussion. Some concerns about this paper have surfaced. 2-day review? The paper (HT to John Borghi) was in review only from March 30-April 1 — so at most 48 hours. Really? That certainly
Concerns surface on Chinese paper on genetic modification of human embryos Read More »
The Juan Carlos Izpisua Belmonte group published a Cell paper today on using gene editing to reverse mutations associated with human mitochondrial disease. The paper is Reddy, et al. and is entitled, “Selective Elimination of Mitochondrial Mutations in the Germline by Genome Editing”. The authors report success using TALEN-based gene editing or mitochondrial-direct restriction enzyme (mito-ApaLI)
Juan Carlos Izpisua Belmonte Cell Paper on Gene Editing for Mitochondrial Disease Read More »
Rumors have been flying for months that researchers in China and possibly elsewhere were shopping papers around at high-profile journals that reported gene editing and genetic modification of human embryos. Update: apparently this paper (HT to @JohnBorghi) was only reviewed for 2 days (see image at bottom of post), raising major concerns about the depth of
Researchers in China make genetically modified human embryos Read More »
I invited the Chief Scientific Officer (CSO) of Bioheart, Kristin Comella, to do an interview after hearing some buzz that this could be a critical time for the company and that it might have been recently visited by the FDA. Note that Comella not just Bioheart CSO, but also the primary instructor for physician training in stem
Interview with Bioheart CSO, Kristin Comella including on FDA Read More »
Controversial TV physician Dr. Mehmet Oz hasn’t had a great year what with his disastrous testimony before Congress. (2020 Update; Dr. Oz recently had a good show on stem cell clinics so that’s something. I discussed issues with his staff prior to the show.) Now Dr. Oz has been slammed by a group doctors from
Doctors call for Dr. Oz to be booted from Columbia Read More »
I’m doing a series of interviews with leaders in the field on human germline modification with the first interview in this series with George Church and today’s second in this series is a conversation I had with Dr. Jennifer Doudna, a pioneer in CRISPR-Cas9 technology. Doudna is a Professor in MCB and Chemistry as well
Jennifer Doudna Interview on CRISPR, Human Gene Editing Read More »
The big stem cell news already this week is the acquisition by Fujifilm of Cellular Dynamics International (CDI) for a whopping $307 million dollars or about $16.50 per CDI share. You can read the press release here. Update: The entity is now known as Fujifilm Cellular Dynamics. It was less than two years ago that CDI did
Was Fujifilm CDI acquisition a good move by the companies? Read More »
By Jane Langille A few weeks ago, I wrote to Dr. Paul Knoepfler after reading his book Stem Cells: An Insider’s Guide because I was intrigued by his stem cell theory of aging. I wondered if his theory might mean that someone who mobilized and donated hematopoietic cells might be shortening their own lifetime supply. After
Risks for Healthy PBSC Donors? One Family’s Powerful Experience Read More »
You might enjoy the recommended reads below and find they surprise and educate you. Products in the pipeline – Ocata’s RPE by Alexey, a nice update on Ocata. Yes, we are seeing more attacks on academic freedom: guest post by historian of science and medicine. Guest piece by Alice Dreger on her new book, Galileo’s Middle Finger.
Weekend Reads from a Wild, Fun Week of Science Read More »